These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2020619)

  • 1. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356).
    Wynant GE; Murphy GP; Horoszewicz JS; Neal CE; Collier BD; Mitchell E; Purnell G; Tyson I; Heal A; Abdel-Nabi H
    Prostate; 1991; 18(3):229-41. PubMed ID: 2020619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
    Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
    Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
    Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
    Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
    Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
    Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC
    Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer imaging with a new monoclonal antibody: a preliminary report.
    Sanford E; Grzonka R; Heal A; Helal M; Persky L; Tyson I
    Ann Surg Oncol; 1994 Sep; 1(5):400-4. PubMed ID: 7850541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
    Doerr RJ; Herrera L; Abdel-Nabi H
    Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study.
    Doerr RJ; Abdel-Nabi H; Krag D; Mitchell E
    Ann Surg; 1991 Aug; 214(2):118-24. PubMed ID: 1867518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
    Kahn D; Williams RD; Seldin DW; Libertino JA; Hirschhorn M; Dreicer R; Weiner GJ; Bushnell D; Gulfo J
    J Urol; 1994 Nov; 152(5 Pt 1):1490-5. PubMed ID: 7523704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
    Deb N; Goris M; Trisler K; Fowler S; Saal J; Ning S; Becker M; Marquez C; Knox S
    Clin Cancer Res; 1996 Aug; 2(8):1289-97. PubMed ID: 9816299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
    Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
    Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation absorbed dose from indium-111-CYT-356.
    Mardirossian G; Brill AB; Dwyer KM; Kahn D; Nelp W
    J Nucl Med; 1996 Sep; 37(9):1583-8. PubMed ID: 8790224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer.
    Nielsen JT; Poulsen J; Flø C; Marqversen J; Rehling M
    Clin Physiol; 1995 Sep; 15(5):467-81. PubMed ID: 8846667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
    Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
    Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.
    Levesque PE; Nieh PT; Zinman LN; Seldin DW; Libertino JA
    Urology; 1998 Jun; 51(6):978-84. PubMed ID: 9609636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
    Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
    Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma.
    Koizumi M; Endo K; Watanabe Y; Saga T; Sakahara H; Konishi J; Arano Y; Miyachi Y; Kashihara-Sawami M; Imamura S
    Jpn J Cancer Res; 1988 Aug; 79(8):973-81. PubMed ID: 3141332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.